NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
NOVARTIS AG
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026
$150.20−0.42 (-0.28%)
Close on Oct 19, 2026
- Market cap
- $287.48B
- P/E (TTM)
- 21.0
- Dividend yield
- –
NOVARTIS AG revenue by segment
By business segment
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz | – | – | – | $1.45B | $1.60B | $1.04B | $551.00M | $1.33B | $1.37B | $1.45B | – |
| Corporate | – | – | – | -$1.04B | -$599.00M | -$63.00M | -$752.00M | -$800.00M | -$261.00M | -$471.00M | – |
| Alcon [member] | – | – | – | – | – | – | – | -$194.00M | -$3.00M | $39.00M | – |
| Innovative Medicines | – | – | – | $8.79B | $10.69B | $9.17B | $9.29B | $7.87B | $7.60B | $7.26B | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Novartis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.